Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy for head and neck cancer: what about the skin?

NCT ID NCT01647555

Symptom relief Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at skin problems in 57 patients with advanced head and neck cancer who received a combination of the drug cetuximab and radiation therapy. The goal was to track and understand skin side effects during treatment. Researchers also measured quality of life and tumor response, but the main focus was on managing skin reactions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cetuximab
What this could lead to
If successful, this could help doctors better manage skin side effects from this combination treatment, improving patient comfort during therapy.
What could go wrong
This is a small, completed study focused only on side effects, not on whether the treatment works better than alternatives. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

57 people

The number who actually took part.

Started

Oct 2006

Finished

Oct 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with epidermoid head and neck cancer locally advanced

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Epidermoid head and neck carcinoma locally advanced * Indication of Cetuximab and radiotherapy * Karnofsky \>= 60 * Patients participating to another compatible study could be included after consultation with the study director Patients could be beforehand treated for an other ORL cancer The radiotherapy will be delivered for curative aim (minimal dose 66 Gy) Exclusion Criteria: * other histology * Metastatic disease * Recurrent patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epidermoid head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epidermoid head and neck cancer

Contacts and locations

Locations

  • Centre Bourgogne

    Lille, 59000, France

  • Centre Galilée

    Lille, 59045, France

  • Centre Gray

    Maubeuge, 59600, France

  • Centre Joliot Curie

    Saint-Martin-Boulogne, 62280, France

  • Centre Leonard de Vinci

    Douai, 59500, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Clinique du Parc

    Croix, 599962, France